Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Enanta Pharmaceuticals (ENTA)
NASDAQ:ENTA
RESEARCH TOOLSreports
Holding ENTA?
Track your performance easily
ENTA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$8.51 - $17.80
Previous Close$9.08
Volume183.97K
Average Volume (3M)150.40K
Market Cap
$203.11M
Enterprise Value$20.08M
Total Cash (Recent Filing)$230.09M
Total Debt (Recent Filing)$50.57M
Price to Earnings (P/E)―
Beta1.18
Next Earnings
Nov 25, 2024EPS Estimate
-$1.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.46
Shares Outstanding21,188,571
10 Day Avg. Volume115,117
30 Day Avg. Volume150,404
Standard Deviation0.16
R-Squared0.03
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)1.29
Price to Sales (P/S)2.77
Price to Cash Flow (P/CF)-3.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.28
Enterprise Value/Gross Profit0.25
Enterprise Value/Ebitda-0.17
Forecast
1Y Price Target
$25.00Price Target Upside170.56% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Enanta Pharmaceuticals News
PremiumPre-Earnings
Is ENTA a Buy, Before Earnings?
Bulls Say, Bears Say
Bulls Say
Analyst OpinionAnalyst reiterates a Market Outperform rating for Enanta Pharmaceuticals, reflecting confidence in the company's prospects.
Market PositionThe discontinuation of Pfizer's fusion inhibitor sisunatovir for business reasons could benefit Enanta Pharmaceuticals if its candidates succeed.
Product DevelopmentEDP-323's anti-viral capability validated by this challenge study is seen as a crucial milestone for Enanta.
Bears Say
Clinical TrialsClinical trial failures of planned and ongoing studies could pose significant risks to the investment thesis and target price.
Market SentimentInvestor enthusiasm is somewhat contingent on whether the RSVPEDs readout testing zelicapavir in pediatric patients can demonstrate clinically meaningful utility in higher-risk patients.
Regulatory ApprovalFailure to secure regulatory approval of EDP-938, EDP-323, or EDP-514 could impact the company negatively.
---
Ownership Overview
7.02% Insiders
13.51% Mutual Funds
31.93% Other Institutional Investors
36.65% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ENTA FAQ
What was Enanta Pharmaceuticals’s price range in the past 12 months?
Enanta Pharmaceuticals lowest stock price was $8.51 and its highest was $17.80 in the past 12 months.
What is Enanta Pharmaceuticals’s market cap?
Currently, no data Available
When is Enanta Pharmaceuticals’s upcoming earnings report date?
Enanta Pharmaceuticals’s upcoming earnings report date is Nov 25, 2024 which is in 4 days.
How were Enanta Pharmaceuticals’s earnings last quarter?
Enanta Pharmaceuticals released its earnings results on Aug 05, 2024. The company reported -$1.07 earnings per share for the quarter, beating the consensus estimate of -$1.432 by $0.362.
Is Enanta Pharmaceuticals overvalued?
According to Wall Street analysts Enanta Pharmaceuticals’s price is currently Undervalued.
Does Enanta Pharmaceuticals pay dividends?
Enanta Pharmaceuticals does not currently pay dividends.
What is Enanta Pharmaceuticals’s EPS estimate?
Enanta Pharmaceuticals’s EPS estimate is -$1.16.
How many shares outstanding does Enanta Pharmaceuticals have?
Enanta Pharmaceuticals has 21,188,572 shares outstanding.
What happened to Enanta Pharmaceuticals’s price movement after its last earnings report?
Enanta Pharmaceuticals reported an EPS of -$1.07 in its last earnings report, beating expectations of -$1.432. Following the earnings report the stock price went up 1.167%.
Which hedge fund is a major shareholder of Enanta Pharmaceuticals?
Among the largest hedge funds holding Enanta Pharmaceuticals’s share is Farallon Capital Management, L.L.C.. It holds Enanta Pharmaceuticals’s shares valued at 22M.
---
Enanta Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$25.00 (170.56% Upside)
$25.00 (170.56% Upside)
Hedge Fund Trend
Increased
By 13.3K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Negative
20 days / 200 days
Momentum
1.56%
12-Months-Change
Fundamentals
Return on Equity
-59.64%
Trailing 12-Months
Asset Growth
-19.46%
Trailing 12-Months
Company Description
Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc. operates as a biotechnology company. It engages in the research and development of molecule drugs for the treatment of viral infections and liver diseases. The firm offers the medicine under the brands Mavyret and Viekira Pak. The company was founded by Peter O. Kliem and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.
---
ENTA Company Deck
---
ENTA Earnings Call
Q2 2024
0:00 / 0:00
---
ENTA Stock 12 Month Forecast
Average Price Target
$25.00
▲(170.56% Upside)
Technical Analysis
Best Analysts Covering ENTA
1 Year
1 Year Success Rate
8/18 ratings generated profit
1 Year Average Return
+4.99%
assigned a buy rating 4 months ago
Copying Liisa Bayko's trades and holding each position for 1 Year would result in 44.44% of your transactions generating a profit, with an average return of +4.99% per trade.
---